United Therapeutics Corporation (UTHR) Stock

United Therapeutics Corporation (UTHR) is a Healthcare stock trading at $536.39 (as of 2026-06-18), with a market capitalization of $22.74B and a trailing P/E of 19.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

United Therapeutics Corporation is a biotechnology company that develops and commercializes therapies for chronic and life-threatening diseases. Its portfolio includes treatments for pulmonary arterial hypertension and related conditions, as well as an antibody therapy for high-risk neuroblastoma, with products sold in the United States and internationally.

Valuation — source: SEC EDGAR (first-party)
Price	$536.39
Market Cap	$22.74B
P/E Ratio	19.8
EV / EBITDA	14.1
Price / Book	3.85
Price / Sales	7.18
DCF Value (model)	$339.82
DCF Upside vs Price	-36.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$3.18B
Net Margin	41.9%
Return on Equity	21.8%
Current Ratio	4.79
Revenue Growth (YoY)	-1.6%
EPS Growth (YoY)	-12.0%
FCF Growth (YoY)	-6.2%

Financial Health — source: SEC EDGAR
Altman Z-Score	8.22 (safe)

Valuation vs Sector & Industry
Stock P/E	19.8
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-5.5%
vs Industry	14.8%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($3.20B)
Institutional Holders Tracked	10
Congressional Trades (recent)	3

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Martine A. Rothblatt
Employees	1,305
Country	US
IPO Date	1999-06-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by revenue (market cap unavailable); US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.